112 related articles for article (PubMed ID: 26689604)
1. Design optimisation for pharmacokinetic modeling of a cocktail of phenotyping drugs.
Nguyen TT; Bénech H; Delaforge M; Lenuzza N
Pharm Stat; 2016; 15(2):165-77. PubMed ID: 26689604
[TBL] [Abstract][Full Text] [Related]
2. A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail.
Nguyen TT; Bénech H; Pruvost A; Lenuzza N
Eur J Clin Pharmacol; 2016 Jan; 72(1):39-51. PubMed ID: 26490357
[TBL] [Abstract][Full Text] [Related]
3. Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes.
Chenel M; Bouzom F; Aarons L; Ogungbenro K
J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):635-59. PubMed ID: 19130188
[TBL] [Abstract][Full Text] [Related]
4. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
5. Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.
Dumont C; Mentré F; Gaynor C; Brendel K; Gesson C; Chenel M
Clin Pharmacokinet; 2013 Jan; 52(1):43-57. PubMed ID: 23212609
[TBL] [Abstract][Full Text] [Related]
6. PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models.
Dumont C; Lestini G; Le Nagard H; Mentré F; Comets E; Nguyen TT;
Comput Methods Programs Biomed; 2018 Mar; 156():217-229. PubMed ID: 29428073
[TBL] [Abstract][Full Text] [Related]
7. Proximal Roux-en-Y gastric bypass alters drug absorption pattern but not systemic exposure of CYP3A4 and P-glycoprotein substrates.
Chan LN; Lin YS; Tay-Sontheimer JC; Trawick D; Oelschlager BK; Flum DR; Patton KK; Shen DD; Horn JR
Pharmacotherapy; 2015 Apr; 35(4):361-9. PubMed ID: 25757445
[TBL] [Abstract][Full Text] [Related]
8. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.
Reitman ML; Chu X; Cai X; Yabut J; Venkatasubramanian R; Zajic S; Stone JA; Ding Y; Witter R; Gibson C; Roupe K; Evers R; Wagner JA; Stoch A
Clin Pharmacol Ther; 2011 Feb; 89(2):234-42. PubMed ID: 21191377
[TBL] [Abstract][Full Text] [Related]
9. A general method to determine sampling windows for nonlinear mixed effects models with an application to population pharmacokinetic studies.
Foo LK; McGree J; Duffull S
Pharm Stat; 2012; 11(4):325-33. PubMed ID: 22411749
[TBL] [Abstract][Full Text] [Related]
10. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods.
Jordan P; Brunschwig H; Luedin E
Pharm Stat; 2008; 7(1):36-41. PubMed ID: 17335108
[TBL] [Abstract][Full Text] [Related]
11. Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.
Neuhoff S; Yeo KR; Barter Z; Jamei M; Turner DB; Rostami-Hodjegan A
J Pharm Sci; 2013 Sep; 102(9):3161-73. PubMed ID: 23686764
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
13. The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.
Kakuda TN; Van Solingen-Ristea RM; Onkelinx J; Stevens T; Aharchi F; De Smedt G; Peeters M; Leopold L; Hoetelmans RM
J Clin Pharmacol; 2014 Apr; 54(4):422-31. PubMed ID: 24165884
[TBL] [Abstract][Full Text] [Related]
14. Multiplex Phenotyping for Systems Medicine: A One-Point Optimized Practical Sampling Strategy for Simultaneous Estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 Activities Using a Cocktail Approach.
de Andrés F; Terán S; Bovera M; Fariñas H; Terán E; LLerena A
OMICS; 2016 Feb; 20(2):88-96. PubMed ID: 26600202
[TBL] [Abstract][Full Text] [Related]
15. CombiCap: A novel drug formulation for the basel phenotyping cocktail.
Camblin M; Berger B; Haschke M; Krähenbühl S; Huwyler J; Puchkov M
Int J Pharm; 2016 Oct; 512(1):253-261. PubMed ID: 27566010
[TBL] [Abstract][Full Text] [Related]
16. Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics.
Retout S; Mentré F; Bruno R
Stat Med; 2002 Sep; 21(18):2623-39. PubMed ID: 12228881
[TBL] [Abstract][Full Text] [Related]
17. A pragmatic approach to the design of population pharmacokinetic studies.
Roy A; Ette EI
AAPS J; 2005 Oct; 7(2):E408-20. PubMed ID: 16353920
[TBL] [Abstract][Full Text] [Related]
18. Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study.
Derungs A; Donzelli M; Berger B; Noppen C; Krähenbühl S; Haschke M
Clin Pharmacokinet; 2016 Jan; 55(1):79-91. PubMed ID: 26123704
[TBL] [Abstract][Full Text] [Related]
19. Influence of covariance between random effects in design for nonlinear mixed-effect models with an illustration in pediatric pharmacokinetics.
Dumont C; Chenel M; Mentré F
J Biopharm Stat; 2014; 24(3):471-92. PubMed ID: 24697342
[TBL] [Abstract][Full Text] [Related]
20. Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters.
Comets E; Verstuyft C; Lavielle M; Jaillon P; Becquemont L; Mentré F
Eur J Clin Pharmacol; 2007 May; 63(5):437-49. PubMed ID: 17404720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
